WVP
TPST icon

Worth Venture Partners’s Tempest Therapeutics TPST Stock Holding History

Worth Venture Partners’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-7,812
Closed -$31.8K – 168
2023
Q3 		$31.8K Hold
7,812
– – 0.02% 137
2023
Q2 		$129K Buy
+7,812
New +$197K 0.07% 127
2019
Q2 		– Sell
-94
Closed -$276K – 111
2019
Q1 		$276K Sell
94
-39
-29% -$86.3K 0.15% 63
2018
Q4 		$206K Buy
133
+97
+269% +$200K 0.16% 64
2018
Q3 		$77K Buy
+36
New +$86.5K 0.06% 117

Other funds holding TPST

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Worth Venture Partners's TPST Position: Q4 2023 in Review

Worth Venture Partners sold out of Tempest Therapeutics (TPST) in Q4 2023, closing a stake of 7,812 shares — an estimated $31.8K sold.

Worth Venture Partners first reported a position in TPST in Q3 2018 and held it in 5 quarters. The position peaked at $276K in Q1 2019. 31 funds tracked by Wall St. Rank hold TPST as of Q4 2023.

  • Worth Venture Partners reported no remaining Tempest Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Worth Venture Partners sold 7,812 Tempest Therapeutics shares in Q4 2023, an estimated $31.8K.
  • Worth Venture Partners first reported a position in Tempest Therapeutics in Q3 2018 and held it in 5 quarters.
  • Worth Venture Partners's Tempest Therapeutics position peaked at $276K in Q1 2019.
  • 31 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2023.

Based on Worth Venture Partners's 13F filing for Q4 2023, filed 9 Feb 2024.